The Latest Breaking News from Pfizer

These three stocks pay out an attractive yield.

Pfizer stock closed flat Thursday after the company pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Fall means it’s time for just about everybody to get up to date on their flu and COVID-19 vaccines

The new kits were supposed to be available for order on Monday

Migraine drugs can represent big money for pharmaceutical firms, as shown when Pfizer acquired Biohaven -- which developed rimegepant -- for more than $10 billion in 2022.

The U.S. is coming down from its biggest COVID summer surge yet as a new subvariant emerges—but new vaccines are here, too.

Patrick Ruane, 55, from Paddington, west London, weaponised social media app Telegram to encourage attacks

COVID vaccines have unquestionably made a huge difference during this pandemic. For example, it’s estimated COVID shots have saved more than 1.4 million lives in the World Health Organization’s (WHO) European region alone since their introduction in December 2020.

A New York City mural honoring ancient and modern figures in medicine could end up in pieces if it can’t find a new patron soon

While technology stocks continue to struggle, stocks in the lucrative over-the-counter healthcare products sector are thriving. One prominent such name is Haleon. Its stock has jumped more than 22% over the past three months, as sales and profits in its nine large-scale multinational, high-margin 'power brands' continue to hold leading…

Although Pfizer underperformed the Dow Jones this year, analysts are moderately bullish on the stock’s prospects.